Jiuzhitang Co., Ltd.
Jiuzhitang Co., Ltd. (“Jiuzhitang”) is a key state Chinese Medicine enterprise, a key state high-tech enterprise, an A-share listed company, winner of the Quality Management Award of Hunan Province, and a national post-doctoral research workstation. "Lao Jiuzhitang Herbal Medicine Shop", predecessor of Jiuzhitang was founded in 1650. In February 2004, the “Jiuzhitang” trademark was officially recognized as a “China Famous Brand” by the Trademark Office of the State Administration for Industry and Commerce; in September 2006, “Jiuzhitang” was selected as “Chinese Time-honored Brand” by Ministry of Commerce; June 2008, Jiuzhitang Traditional Chinese Medicine culture was included in the “National Intangible Cultural Heritage” protection catalogue. The Jiuzhitang brand has been selected as one of the top 500 most valuable brands in China for five consecutive years, and reached a value of RMB 11.155 billion in 2017.
The main business of Jiuzhitang covers R&D, production and sales of Chinese patent medicine. Now the company has developed into a large-scale modern pharmaceutical enterprise with several subsidiaries and hundreds of chain stores, integrating production, sales, scientific research and health services. While focusing on development of its main business, Jiuzhitang has been actively exploring a new model of the health industry and launched a series of refined medicinal slices, thus cultivating a cluster of comprehensive health products based on the concept of “Food is Medicine”. At the same time, in order to spread the concept of "treat people before they get sick", Jiuzhitang gathered famous TCM specialists at home and abroad, introduced special medical projects, concentrated on building a multi-functional health service building integrating “medicine, medical treatment, health maintenance, learning and overseas study tour”, promoted Chinese medicine culture, popularized and expanded the influence of Chinese medicine, all of which contribute to a leap from focusing on pharmaceuticals to carrying forward traditional culture.
Relying on the state-level scientific research platform, Jiuzhitang has joined hands with top research institutes at home and abroad to carry out all-round cooperation in production, learning and research, and has undertaken a number of scientific and technological projects such as major national new drug creation and national key research and development programs. The inheritance and innovation of Chinese medicinal slices processing technology, the secondary development of large-scale Chinese medicine, and the research and development of new drugs have achieved fruitful results, and have begun to show their prominence in the fields of regenerative medicine. In the future, Jiuzhitang will be committed to doing a good job of “integration of old and new, integration of inheritance and innovation, integration of beliefs and beliefs, and integration of culture”, polishing the brand of Jiuzhitang for centuries and making greater contributions to advancement of human health.
As a pharmaceutical company with a history of over 100 years, Jiuzhitang Co., Ltd. made prospectively the strategic decision of reconfiguring the landscape of regenerative medicine by giving full play to its advantages as a player in the traditional Chinese medicine industry and leveraging world’s leading stem cell technologies. This effort aims at combining cutting-edge stem cell technologies with traditional Chinese medicine, so as to set a good example for Chinese corporations with time-honored brands to pursue innovative business
Founded in March 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (“Jiuzhitang”) is a biotechnology company focused on the manufacture, R&D and sales of stem cell-based drugs and regenerative care products. Jiuzhitang Maker was established with an investment of 200 million yuan made by Yonghe Qihang Fund initiated by Jiuzhitang Co., Ltd. (“Jiuzhitang”, stock code: sz000989).
Jiuzhitang Maker built a large-scale allogenic stem cells R&D and manufacturing facility that meets Chinese, US and EU cGMP standards in ZGC Biomedicine Industry Park, Daxing District, the first of its kind in Beijing. Covering an area approximating 4500m2, the facility has 4 separate Grade B+A clean areas dedicated to the manufacture of clinical grade stem cell products compliant with Chinese and US drug application requirements.
By importing Stemedica’s world leading BioSmart technology platform characterized by proprietary hypoxic manufacturing environment, Jiuzhitang Maker will acquire the core technology that holds key to the scalable, standardized and traceable production of clinical grade stem cell products. The output of stem cell products achieved by this US cGMP compliant platform ranks NO.1 in the world with no compromise to product safety and efficacy. This unique advantage successfully solved the technical challenges involved in making stem cells into drugs.
Jiuzhitang Maker has been selected as one of the Top 10 Key Enterprises by the Development and Reform Commission of Daxing District and the management committee of the Biomedicine Industry Park, and have been awarded titles including “ZGC High-Tech Enterprise”, “National High-Tech Enterprise” and “ZGC Gold Seed Enterprise”. “A Pre-clinical Study Using Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat Acute Cerebral Stroke” and “Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Lung Injuries Caused by COVID-19”, two research projects JZT Maker plans to launch were both approved by relevant authorities, and received fund support from Beijing Science and Technology Major Project initiative, Daxing District Program for Better Development of the Healthcare Industry, and funding provided by a Daxing Science and Technology Commission initiative to COVID-19 epidemic prevention and control projects.
Jiuzhitang Maker received IND approval for stem cell therapy in February 2020. The clinical trial Maker intends to launch is the first CDE-approved study using an imported stem cell product, the first study treating a major neurological indication with stem cells, and the first study evaluating bone marrow-derived mesenchymal stem cells since National Medical Products Administration resumed review of IND applications for stem cell therapy.
Looking into the future, Jiuzhitang Maker will work tirelessly to shorten the time needed to launch stem cell drugs in the domestic market, and further satisfy humankind’s multi-level and multi-aspect health needs by utilizing forefront achievements made in studies into regenerative medicine.
Stemedica Cell Technologies, Inc.
Founded in 2005, Stemedica Cell Technologies, Inc. is one of the world’s few corporations that are capable of manufacturing both human bone marrow-derived mesenchymal stem cells and human neural stem cells. Through 15 years’ development since establishment, Stemedica has created a proprietary hypoxic stem cells production platform named BioSmart, which is able to realize a manufacturing capacity significantly greater than most of its competitors. Stemedica and its partners have published 15 high-impact research papers and filed application for 26 patents, among which 7 have been approved so far.
Secretion of cytokines, homing and tissue repair capabilities, and responses to inflammation demonstrated by Stemedica’s stem cells are remarkably superior to stem cells cultured under normal conditions, which enables the company to be selected as “Best-in-Class” supplier of stem cells by Life Technologies. Stemedica has launched 7 clinical trials in the United States and 11 in other countries using bone marrow-derived mesenchymal stem cell and neural stem cell products. In particular, its mesenchymal stem cells have been approved and listed by the Ministry of Health of Kazakhstan as a treatment of acute myocardial infarction.
Jiuzhitang-ALTACO International Healthcare Center
Responding to calls of the Belt and Road Initiative, Jiuzhitang Co., Ltd. and ALTACO XXI from Kazakhstan jointly built the Jiuzhitang-ALTACO International Healthcare Center in China-Kazakhstan Khorgos International Frontier Cooperation Center. Staring business in September 2019, the center will serve as a platform for innovative cooperation in launching scientific studies on stem cells and translating research findings into clinical practice.